Curanex Pharmaceuticals Inc Common Stock (CURX) vs Enveric Biosciences, Inc. (ENVB)

A side-by-side comparison of Curanex Pharmaceuticals Inc Common Stock and Enveric Biosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Curanex Pharmaceuticals Inc Common Stock logo
CURX
Curanex Pharmaceuticals Inc Common Stock
$7M
$4.96HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Enveric Biosciences, Inc. logo
ENVB
Enveric Biosciences, Inc.
$7M
$1.51HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — CURX vs ENVB

growth of $100 · dividends reinvested · last 1y
CURX -91.8% (-91.8%/yr)ENVB -66.7% (-66.7%/yr)ENVB compounded faster over this window
050100150200Start $1002026$8$33
CURX ENVB

CURX vs ENVB: by the numbers

  • •CURX is the larger company ($7M vs $7M market cap).

Metrics side by side

Valuation

MetricCURXENVB
P/B ratio1.470.84

Profitability

MetricCURXENVB
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-218.65%-108.00%
ROIC-208.39%-107.99%

Go deeper

Full CURX analysisFull ENVB analysisInteractive comparison tool

Dig into the metrics

Curanex Pharmaceuticals Inc Common Stock ROEEnveric Biosciences ROECuranex Pharmaceuticals Inc Common Stock operating marginEnveric Biosciences operating marginCuranex Pharmaceuticals Inc Common Stock revenue growthEnveric Biosciences revenue growthCuranex Pharmaceuticals Inc Common Stock free cash flowEnveric Biosciences free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.